Traveler's Diarrhea Epidemiology Forecast 2025-2034

Traveler’s diarrhea is a highly prevalent travel-related gastrointestinal infection. Depending on the destination and season, the condition affects between 30% and 70% of travelers. Traveler’s diarrhea is observed to be more common in regions with hot and humid climates.

Traveler’s Diarrhea Epidemiology Forecast Report Coverage

The “Traveler’s Diarrhea Epidemiology Forecast Report 2025-2034” offers comprehensive information on the prevalence and demographics of traveler’s diarrhea. It projects the future incidence and prevalence rates of traveler’s diarrhea across various populations. The study covers age and type as major determinants of the traveler’s diarrhea-affected population. The report highlights patterns in the prevalence of traveler’s diarrhea over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on the epidemiology of traveler’s diarrhea in the 8 major markets.

Regions Covered

• The United States
• Germany
• France
• Italy
• Spain
• The United Kingdom
• Japan
• India

Traveler’s Diarrhea: Disease Overview

Traveler’s diarrhea commonly affects international travelers when they consume contaminated food or water. Diarrhea, abdominal cramps, fever, nausea, and vomiting are the common symptoms. The infection that causes traveler’s diarrhea can be bacterial, viral, or parasitic. People with weak immune systems and underlying chronic gastrointestinal issues (such as Crohn’s disease or irritable bowel syndrome) are more likely to develop this condition.

Traveler’s Diarrhea: Treatment Overview

If symptoms of traveler’s diarrhea are severe, antidiarrheals or antibiotics are prescribed to the patient. Antidiarrheal drugs, such as Atropine diphenoxylate (Lomotil®), Bismuth (Pepto-Bismol®), and Loperamide (Imodium®), are widely used to slow the muscle contractions that move the bowels. In case of a severe bacterial infection or if diarrhea persists for more than a few days, antibiotics like Ciprofloxacin (Cipro®), Levofloxacin (Levaquin®), and Azithromycin (Zmax®) are given to the patient.

Epidemiology

The traveler’s diarrhea epidemiology section offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. The publisher provides both current and predicted trends for traveler’s diarrhea by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for traveler’s diarrhea and their trends. The data is broken down into specific categories, such as the total diagnosed cases across different age groups and patient pools.

• Traveler’s diarrhea is considered the most common travel-associated condition, with estimates indicating that around 40% to 60% of travelers experience the infection depending on their travel region.
• According to a 2024 systematic review, around 20% to 56% of international travelers can expect to experience traveler’s diarrhea in travel of under 100 days, with the majority of the cases showing mild symptoms and only about 3% facing disruption in their usual activities due to the disease or requiring medical attention.
• Studies show that enterotoxigenic Escherichia coli (ETEC) is the most common bacterial cause of traveler’s diarrhea, accounting for approximately 30% of cases. Norovirus and Giardia intestinalis are the most common viral and parasitic causes, respectively.
• It is observed that symptoms of traveler’s diarrhea typically start 12 to 72 hours after the consumption of infected food or water, and usually lasts for 3 to 5 days.

Country-wise Traveler’s Diarrhea Epidemiology

The traveler’s diarrhea epidemiology data and findings for the United States, EU-4 (Germany, Spain, Italy, France), the United Kingdom, Japan, and India are also provided in the epidemiology section.

The epidemiology of traveler’s diarrhea varies significantly between countries due to differences in hygiene practices, sanitation infrastructure, climate, local disease patterns, and the socioeconomic status of the destination. The highest incidence of traveler’s diarrhea is reported in sub-Saharan Africa. South Asia, the Middle East, and Latin America also include regions with high incidence of the condition.

Scope of the Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of traveler’s diarrhea based on several factors.
• Traveler’s Diarrhea Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The report helps to identify the patient population, and the unmet needs of traveler’s diarrhea are highlighted along with an assessment of the disease's risk and burden.

Key Questions Answered

• What are the key findings of traveler’s diarrhea epidemiology in the 8 major markets?
• What will be the total number of patients with traveler’s diarrhea across the 8 major markets during the forecast period?
• What was the country-wise prevalence of traveler’s diarrhea in the 8 major markets in the historical period?
• Which country will have the highest number of traveler’s diarrhea patients during the forecast period of 2025-2034?
• Which key factors would influence the shift in the patient population of traveler’s diarrhea during the forecast period of 2025-2034?
• What are the currently available treatments for traveler’s diarrhea?
• What are the disease risks, signs, symptoms, and unmet needs of traveler’s diarrhea?

This product will be delivered within 3-5 business days.